COMMUNIQUÉS West-GlobeNewswire

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results
15/05/2026
Completed enrollment in first cohort of Phase 1b challenge study evaluating CDI-988 as a preventive and as a treatment for norovirus infection, began enrollment in prevention and treatment cohorts Highlighted CDI-988’s [...]
Vaso Corporation Announces Financial Results for First Quarter of 2026
15/05/2026
PLAINVIEW, N.Y., May 15, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional sales services, and [...]
GT Biopharma Reports First Quarter 2026 Financial Results
15/05/2026
Phase 1 trial evaluating GTB-3650 TriKE ® remains ongoing, with additional updates anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE ® in multiple solid tumor types known to express B7-H3 initiated [...]
Oncotelic Therapeutics Files First Quarter 2026 Financial Results and Strategic Progress
15/05/2026
Agoura Hills, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology, AI-enabled drug development, [...]
Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results
15/05/2026
Entering a Transformative Stage by Advancing PRP to a Pivotal, Phase 1b, FIH, Clinical Study Whilst Undertaking Additional Research into Age-Related Chronic Diseases MELBOURNE, Australia, May 15, 2026 (GLOBE NEWSWIRE [...]
Federal Court Motion Raises Questions About Testimony and Outpatient Hysteroscopy Practices in Case Against Memphis Gynecologic Surgeon Dr. Sanjeev Kumar
15/05/2026
MEMPHIS, Tenn., May 15, 2026 (GLOBE NEWSWIRE) -- A supplemental motion for a new trial filed last month in federal court raises questions about testimony presented during the criminal trial of Memphis gynecologic [...]
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update
15/05/2026
Company to continue development of efzofitimod in pulmonary sarcoidosis following Type C meeting with the FDA. Company plans to submit an IND in June 2026 for a Phase 3 study of efzofitimod in patients with chronic, [...]
Sienna Announces May Dividend
15/05/2026
MARKHAM, Ontario, May 15, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (“ Sienna ” or the “ Company ”) (TSX: SIA) today announced a dividend of $0.078 per common share of the Company (each, a “ Common Share ”) for [...]
Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)
15/05/2026
SAN DIEGO, May 15, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc. (NASDAQ: BLTE), (“Belite Bio®” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics [...]
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
15/05/2026
FDA accepted sNDA for IGALMI® use in at-home (outpatient) setting; set Nov. 14, 2026, as PDUFA date Advancing BXCL501 as a potential acute treatment for agitation associated with Alzheimer’s dementia Evaluating [...]
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
15/05/2026
TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response rate at the 12-month landmark in BCG-Naïve patients Favorable safety and [...]
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
15/05/2026
100% of patients with bleeding at baseline demonstrated a statistically significant improvement on the Cutaneous Venous Malformations Investigator Global Assessment Bleeding scale (cVM-IGA Bleeding) at Week 12 (+2.5 [...]
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
15/05/2026
Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026 AACR and ASGCT presentations showcase durable survival and [...]
Satellos Reports First Quarter 2026 Financial Results and Highlights Company Progress
15/05/2026
Eleven clinical trial sites in BASECAMP currently active; remaining planned sites to be activated throughout Q2 2026 BASECAMP remains on track to complete enrollment in Q3 2026 The Company has initiated the TRAILHEAD [...]
Davos Alzheimer’s Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer’s Policy, Research and Care
15/05/2026
Davos Alzheimer’s Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contributions to Alzheimer’s Policy, Research and Care Geneva, Switzerland, May 15, 2026 - The Davos Alzheimer’s [...]
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
15/05/2026
NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company, today announced financial results for the first quarter ended [...]
Kanghong Pharmaceutical and Vanotech Announce Positive Phase 2b Results for KH607 in Major Depressive Disorder
15/05/2026
Phase 2b Trial Met Primary Endpoint, Demonstrating Strong Efficacy and Favorable Safety Profile; Phase 3 Planned CHENGDU, China and ROCKAWAY, N.J., May 15, 2026 (GLOBE NEWSWIRE) -- Kanghong Pharmaceutical and Vanotech [...]
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
15/05/2026
BEDFORD, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular” or the “Company”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced [...]
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
15/05/2026
Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer. Initial focus on patient selection, treatment planning and post-treatment monitoring; [...]

Pages